Funder
National Natural Science Foundation of China
Subject
Pharmacology,Biochemistry
Reference167 articles.
1. Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100;Nishio;Cancer Sci.,2020
2. T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028;Ott;J. Clin. Oncol.,2019
3. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study;Matulonis;Ann. Oncol.,2019
4. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012
5. The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019;Ascierto;J. Immunother. Cancer,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献